Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression and mislocalization of epidermal growth factor receptor (EGFR) to the apical membranes of cystic epithelial cells. Nimotuzumab is a humanized antibody that recognizes an extracellular domain...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacology 2019-06, Vol.59 (6), p.863-871
Main Authors: Castro‐Suárez, Niurys, Rodríguez‐Vera, Leyanis, Villegas, Carlos, Dávalos‐Iglesias, José M., Bacallao‐Mendez, Raymed, Llerena‐Ferrer, Betsy, Leyva‐de la Torre, Christian, Lorenzo‐ Luaces, Patricia, Troche‐Concepción, Mayelin, Ramos‐Suzarte, Mayra
Format: Article
Language:English
Subjects:
autosomal dominant polycystic kidney disease
EGFR
Epidermal growth factor
Epidermal growth factor receptors
Epithelial cells
Immunotherapy
Intravenous administration
Kidney diseases
Kidneys
Kinetics
Membranes
Monoclonal antibodies
monoclonal antibody
nimotuzumab
Patients
Pharmacokinetics
Polycystic kidney
Sodium
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression and mislocalization of epidermal growth factor receptor (EGFR) to the apical membranes of cystic epithelial cells. Nimotuzumab is a humanized antibody that recognizes an extracellular domain III of human EGFR. The aim of this study was to assess the pharmacokinetic behavior of nimotuzumab in patients with ADPKD given as a single dose. A phase I, single‐center, and noncontrolled open clinical study was conducted. Five patients were enrolled at each of the following fixed‐dose levels: 50, 100, 200, and 400 mg. Intravenous continuous infusions of nimotuzumab were administered every 14 days during a year, except the first administration, when blood samples were drawn during 28 days for pharmacokinetic assessments. Subjects were closely monitored during the trial and at completion of the administration of nimotuzumab, including the anti‐idiotypic response. For the first time, nimotuzumab was used for treating a nononcological disease. The administration of nimotuzumab showed dose‐dependent kinetics. Nimotuzumab does not develop anti‐idiotypic response against the murine portion present in the hypervariable region of the antibody present in the serum of the patients treated. No significant differences were found in the systemic clearance between the 100‐ and 400‐mg dose, which indicates that the optimal biological dose is in this range of dose.
ISSN:0091-2700
1552-4604
DOI:10.1002/jcph.1376